Clinical Trial Detail

NCT ID NCT03272217
Title Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Arjun Balar, MD
Indications

urethra transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Atezolizumab + Bevacizumab

Atezolizumab

Age Groups: adult senior

No variant requirements are available.